{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:29:25Z","timestamp":1791430165685,"version":"4.3.3"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000},"content-version":"am","delay-in-days":264,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371210"],"award-info":[{"award-number":["32371210"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2023JJ30724"],"award-info":[{"award-number":["2023JJ30724"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007053","name":"Siemens EDA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.neuropharm.2024.110089","type":"journal-article","created":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T20:52:26Z","timestamp":1721422346000},"page":"110089","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Oral edaravone ameliorates behavioral deficits and pathologies in a valproic acid-induced rat model of autism spectrum disorder"],"prefix":"10.1016","volume":"258","author":[{"given":"Xiao-Yu","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Qing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Xuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Hao","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Yu-Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Rong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8068-1237","authenticated-orcid":false,"given":"Chang-Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8687-0175","authenticated-orcid":false,"given":"Xin-Fu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2024.110089_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115199","article-title":"Neuroprotective effect of the standardised extract of Bacopa monnieri (BacoMind) in valproic acid model of autism spectrum disorder in rats","volume":"293","author":"Abhishek","year":"2022","journal-title":"J. Ethnopharmacol."},{"issue":"13","key":"10.1016\/j.neuropharm.2024.110089_bib2","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2174\/0929867326666190124122752","article-title":"Oxidative status in multiple sclerosis and off-targets of antioxidants: the case of edaravone","volume":"27","author":"Agresti","year":"2020","journal-title":"Curr. Med. Chem."},{"issue":"12","key":"10.1016\/j.neuropharm.2024.110089_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.sjbs.2023.103849","article-title":"Glucose transporter 1 deficiency, AMP-activated protein kinase activation and immune dysregulation in autism spectrum disorder: novel biomarker sources for clinical diagnosis","volume":"30","author":"Al-Bishri","year":"2023","journal-title":"Saudi J. Biol. Sci."},{"key":"10.1016\/j.neuropharm.2024.110089_bib4","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13229-018-0221-9","article-title":"Sociability deficits after prenatal exposure to valproic acid are rescued by early social enrichment","volume":"9","author":"Campolongo","year":"2018","journal-title":"Mol. Autism."},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110089_bib5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pathophys.2006.05.007","article-title":"Oxidative stress in autism","volume":"13","author":"Chauhan","year":"2006","journal-title":"Pathophysiology"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110089_bib6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s13311-015-0352-z","article-title":"Phelan-McDermid syndrome and SHANK3: implications for treatment","volume":"12","author":"Costales","year":"2015","journal-title":"Neurotherapeutics"},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110089_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1179\/1351000211Y.0000000012","article-title":"Urinary oxidative stress markers in children with autism","volume":"16","author":"Damodaran","year":"2011","journal-title":"Redox Rep."},{"issue":"10","key":"10.1016\/j.neuropharm.2024.110089_bib8","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1039\/D0FO02926B","article-title":"Maternal folic acid supplementation prevents autistic behaviors in a rat model induced by prenatal exposure to valproic acid","volume":"12","author":"Di","year":"2021","journal-title":"Food Funct."},{"issue":"12","key":"10.1016\/j.neuropharm.2024.110089_bib9","first-page":"CD007230","article-title":"Edaravone for acute ischaemic stroke","author":"Feng","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"issue":"10","key":"10.1016\/j.neuropharm.2024.110089_bib10","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.freeradbiomed.2012.03.011","article-title":"Oxidative stress-related biomarkers in autism: systematic review and meta-analyses","volume":"52","author":"Frustaci","year":"2012","journal-title":"Free Radic. Biol. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2024.110089_bib11","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1542\/peds.2015-2851K","article-title":"Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis","volume":"137","author":"Fung","year":"2016","journal-title":"Pediatrics"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110089_bib12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ajmg.b.30822","article-title":"Novel de novo SHANK3 mutation in autistic patients","volume":"150B","author":"Gauthier","year":"2009","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.neuropharm.2024.110089_bib13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijdevneu.2015.06.006","article-title":"Abnormal transsulfuration metabolism and reduced antioxidant capacity in Chinese children with autism spectrum disorders","volume":"46","author":"Han","year":"2015","journal-title":"Int. J. Dev. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110089_bib14","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1254\/jphs.12025SC","article-title":"Effect of prenatal valproic acid exposure on cortical morphology in female mice","volume":"118","author":"Hara","year":"2012","journal-title":"J. Pharmacol. Sci."},{"issue":"7","key":"10.1016\/j.neuropharm.2024.110089_bib15","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.cell.2013.11.024","article-title":"Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders","volume":"155","author":"Hsiao","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.neuropharm.2024.110089_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.freeradbiomed.2022.02.004","article-title":"Oxidative stress andregeneration","volume":"181","author":"Jaganjac","year":"2022","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110089_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/ng1136","article-title":"Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism","volume":"34","author":"Jamain","year":"2003","journal-title":"Nat. Genet."},{"issue":"16","key":"10.1016\/j.neuropharm.2024.110089_bib18","doi-asserted-by":"crossref","first-page":"5225","DOI":"10.1073\/pnas.1422998112","article-title":"Edaravone alleviates Alzheimer's disease-type pathologies and cognitive deficits","volume":"112","author":"Jiao","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.neuropharm.2024.110089_bib19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.neuro.2016.09.005","article-title":"Streptozotocin inhibits synaptic transmission and edaravone attenuates streptozotocin-induced electrophysiological changes in CA1 pyramidal neurons of rat hippocampal slices","volume":"57","author":"Ju","year":"2016","journal-title":"Neurotoxicology"},{"issue":"8","key":"10.1016\/j.neuropharm.2024.110089_bib20","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10803-012-1723-5","article-title":"Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study","volume":"43","author":"Kent","year":"2013","journal-title":"J. Autism Dev. Disord."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110089_bib21","first-page":"899","article-title":"Beyond neurological disease: new targets for edaravone","volume":"28","author":"Kikuchi","year":"2011","journal-title":"Int. J. Mol. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2024.110089_bib22","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/nn.4353","article-title":"Genome-wide prediction and functional characterization of the genetic basis of autism spectrum disorder","volume":"19","author":"Krishnan","year":"2016","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110089_bib23","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MOP.0b013e328336eb9a","article-title":"What causes autism? Exploring the environmental contribution","volume":"22","author":"Landrigan","year":"2010","journal-title":"Curr. Opin. Pediatr."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110089_bib24","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/cercor\/bhac174","article-title":"Infralimbic YTHDF1 is necessary for thebeneficial effects of acute mild exercise on auditory fear extinction retention","volume":"33","author":"Li","year":"2023","journal-title":"Cerebr. Cortex"},{"issue":"10146","key":"10.1016\/j.neuropharm.2024.110089_bib25","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S0140-6736(18)31129-2","article-title":"Autism spectrum disorder","volume":"392","author":"Lord","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110089_bib26","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/sj.npp.1301453","article-title":"Abnormal fear conditioning and amygdala processing in an animal model of autism","volume":"33","author":"Markram","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2024.110089_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euroneuro.2021.05.010","article-title":"Drug development for autism spectrum disorder (ASD): progress, challenges, and future directions","volume":"48","author":"McCracken","year":"2021","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110089_bib28","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.neures.2009.09.001","article-title":"Nonexploratory movement and behavioral alterations in a thalidomide or valproic acid-induced autism model rat","volume":"66","author":"Narita","year":"2010","journal-title":"Neurosci. Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110089_bib29","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1038\/s41380-022-01506-w","article-title":"Genetics of glutamate and its receptors in autism spectrum disorder","volume":"27","author":"Nisar","year":"2022","journal-title":"Mol. Psychiatr."},{"issue":"6","key":"10.1016\/j.neuropharm.2024.110089_bib30","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1542\/peds.2008-3782","article-title":"Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder","volume":"124","author":"Owen","year":"2009","journal-title":"Pediatrics"},{"issue":"6\u20137","key":"10.1016\/j.neuropharm.2024.110089_bib31","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.bbabio.2010.04.018","article-title":"Mitochondrial dysfunction in autism spectrum disorders: cause or effect","volume":"1797","author":"Palmieri","year":"2010","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2024.110089_bib32","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.2147\/DDDT.S161944","article-title":"Self-nanomicellizing solid dispersion of edaravone: part II: in vivo assessment of efficacy against behavior deficits and safety in Alzheimer's disease model","volume":"12","author":"Parikh","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.neuropharm.2024.110089_bib33","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2147\/DDDT.S161940","article-title":"Self-nanomicellizing solid dispersion of edaravone: part I - oral bioavailability improvement","volume":"12","author":"Parikh","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110089_bib34","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1021\/jp110400t","article-title":"OH radical scavenging activity of Edaravone: mechanism and kinetics","volume":"115","author":"P\u00e9rez-Gonz\u00e1lez","year":"2011","journal-title":"J. Phys. Chem. B"},{"issue":"3","key":"10.1016\/j.neuropharm.2024.110089_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/mp.2010.136","article-title":"Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis","volume":"17","author":"Rossignol","year":"2012","journal-title":"Mol. Psychiatr."},{"issue":"17","key":"10.1016\/j.neuropharm.2024.110089_bib36","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1001\/jama.2014.4144","article-title":"The familial risk of autism","volume":"311","author":"Sandin","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110089_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.npp.1300518","article-title":"Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism","volume":"30","author":"Schneider","year":"2005","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110089_bib38","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.brs.2023.03.006","article-title":"Ultrasound-enhanced brain delivery of edaravone provides additive amelioration on disease progression in an ALS mouse model","volume":"16","author":"Shen","year":"2023","journal-title":"Brain Stimul."},{"issue":"43","key":"10.1016\/j.neuropharm.2024.110089_bib39","doi-asserted-by":"crossref","first-page":"15550","DOI":"10.1073\/pnas.1416940111","article-title":"Sulforaphane treatment of autism spectrum disorder (ASD)","volume":"111","author":"Singh","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110089_bib40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/archdischild-2013-305636","article-title":"Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism","volume":"99","author":"Smith","year":"2014","journal-title":"Arch Dis Child Educ Pract Ed"},{"key":"10.1016\/j.neuropharm.2024.110089_bib41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.physbeh.2015.10.029","article-title":"Edaravone abrogates LPS-induced behavioral anomalies, neuroinflammation and PARP-1","volume":"154","author":"Sriram","year":"2016","journal-title":"Physiol. Behav."},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110089_bib42","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/j.1469-8749.1994.tb11856.x","article-title":"Autism in thalidomide embryopathy: a population study","volume":"36","author":"Str\u00f6mland","year":"1994","journal-title":"Dev. Med. Child Neurol."},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110089_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.pharmthera.2014.05.010","article-title":"Emerging therapies for Parkinson's disease: from bench to bedside","volume":"144","author":"Tarazi","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110089_bib44","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/jcpp.12499","article-title":"Heritability of autism spectrum disorders: a meta-analysis of twin studies","volume":"57","author":"Tick","year":"2016","journal-title":"JCPP (J. Child Psychol. Psychiatry)"},{"issue":"4","key":"10.1016\/j.neuropharm.2024.110089_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153708","article-title":"Protective effects of edaravone in adult rats with surgery and lipopolysaccharide administration-induced cognitive function impairment","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110089_bib46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/cne.24332","article-title":"Protracted dendritic growth in the typically developing human amygdala and increased spine density in young ASD brains","volume":"526","author":"Weir","year":"2018","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2024.110089_bib47","series-title":"Therapies for Children with Autism Spectrum Disorder: Behavioral Interventions Update","author":"Weitlauf","year":"2014"},{"issue":"2","key":"10.1016\/j.neuropharm.2024.110089_bib48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2739\/kurumemedj.58.47","article-title":"Edaravone attenuates impairment of synaptic plasticity in granule cell layer of the dentate gyrus following traumatic brain injury","volume":"58","author":"Yamashita","year":"2011","journal-title":"Kurume Med. J."},{"key":"10.1016\/j.neuropharm.2024.110089_bib49","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.chemosphere.2017.12.086","article-title":"Bisphenol-A antagonizes the rapidly modulating effect of DHT on spinogenesis and long-term potentiation of hippocampal neurons","volume":"195","author":"Yang","year":"2018","journal-title":"Chemosphere"},{"issue":"5","key":"10.1016\/j.neuropharm.2024.110089_bib50","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/1871527315666160413121751","article-title":"Oxidative stress and nitric oxide in autism spectrum disorder and other neuropsychiatric disorders","volume":"15","author":"Yui","year":"2016","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"issue":"1","key":"10.1016\/j.neuropharm.2024.110089_bib51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13229-021-00447-5","article-title":"Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder","volume":"12","author":"Zimmerman","year":"2021","journal-title":"Mol. Autism."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824002582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390824002582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:57:08Z","timestamp":1762214228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390824002582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":51,"alternative-id":["S0028390824002582"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110089","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral edaravone ameliorates behavioral deficits and pathologies in a valproic acid-induced rat model of autism spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2024.110089","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110089"}}